In lower-risk breast cancer patients, Herceptin plus Taxol highly effective

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news